Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2020

Open Access 01-12-2020 | Attention Deficit Hyperactivity Disorder | Research article

Individualizing the dosage of Methylphenidate in children with attention deficit hyperactivity disorder

Authors: Hoda Shirafkan, Javad Mahmoudi-Gharaei, Akbar Fotouhi, Seyyed Ali Mozaffarpur, Mehdi Yaseri, Mostafa Hoseini

Published in: BMC Medical Research Methodology | Issue 1/2020

Login to get access

Abstract

Background

Attention deficit hyperactivity disorder (ADHD) is one of the most common childhood mental health disorders. Stimulant drugs as the most commonly used treatment and first-line therapy for ADHD have side effects. One of the newest approaches to select the best choices and optimize dosages of medications is personalized medicine.

Methods

This historical cohort study was carried out on the data taken from the period of 2008 to 2015. Eligible subjects were included in the study randomly. We used mixed-effects logistic regression models to personalize the dosage of Methylphenidate (MPH) in ADHD. The patients’ heterogeneity was considered using subject-specific random effects, which are treated as the realizations of a stochastic process. To recommend a personalized dosage for a new patient, a two-step procedure was proposed. In the first step, we obtained estimates for population parameters. In the second step, the dosage of the drug for a new patient was updated at each follow-up.

Results

Of the 221 children enrolled in the study, 169 (76.5%) were male and 52 (23.5%) were females. The overall mean age at the beginning of the study is 82.5 (± 26.5) months. In multivariable mixed logit model, three variables (severity of ADHD, time duration receiving MPH, and dosage of MPH) had a significant relationship with improvement. Based on this model the personalized dosage of MPH was obtained.

Conclusions

To determine the dosage of MPH for a new patient, the more the severity of baseline is, the more of an initial dose is required. To recommend the dose in the next times, first, the estimation of random coefficient should be updated. The optimum dose increased when the severity of ADHD increased. Also, the results show that the optimum dose of MPH as one proceeds through the period of treatment will decreased.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rowland AS, Lesesne CA, Abramowitz AJ. The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev. 2002;8(3):162–70.CrossRef Rowland AS, Lesesne CA, Abramowitz AJ. The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev. 2002;8(3):162–70.CrossRef
2.
go back to reference Shooshtary MH, Chimeh N, Najafi M, Mohamadi MR, Yousefi-Nouraie R, Rahimi-Mvaghar A. The prevalence of attention deficit hyperactivity disorder in Iran: a systematic review. Iran J Psychiatry. 2010;5(3):88.PubMedPubMedCentral Shooshtary MH, Chimeh N, Najafi M, Mohamadi MR, Yousefi-Nouraie R, Rahimi-Mvaghar A. The prevalence of attention deficit hyperactivity disorder in Iran: a systematic review. Iran J Psychiatry. 2010;5(3):88.PubMedPubMedCentral
3.
go back to reference Raman SR, Man KK, Bahmanyar S, Berard A, Bilder S, Boukhris T, et al. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry. 2018;5(10):824–35.CrossRef Raman SR, Man KK, Bahmanyar S, Berard A, Bilder S, Boukhris T, et al. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry. 2018;5(10):824–35.CrossRef
4.
go back to reference Antony A. Study of factors influencing treatment adherence in childhood attention deficit hyperactivity disorder in a tertiary healthcare facility. Indian J Psychol Med. 2016;38(1):20.CrossRef Antony A. Study of factors influencing treatment adherence in childhood attention deficit hyperactivity disorder in a tertiary healthcare facility. Indian J Psychol Med. 2016;38(1):20.CrossRef
5.
go back to reference Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet. 2019;51(1):63.CrossRef Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet. 2019;51(1):63.CrossRef
6.
go back to reference Baht M, Grizenko N, Ben-Amor L, Joober R. Obstetric complications in children with attention deficit/hyperactivity disorder and learning disability. McGill J Med. 2005;8(2):109. Baht M, Grizenko N, Ben-Amor L, Joober R. Obstetric complications in children with attention deficit/hyperactivity disorder and learning disability. McGill J Med. 2005;8(2):109.
7.
go back to reference Millichap JG. Etiologic classification of attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(2):e358–e65.CrossRef Millichap JG. Etiologic classification of attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(2):e358–e65.CrossRef
8.
go back to reference Cerrillo-Urbina AJ, García-Hermoso A, Martínez-Vizcaíno V, Pardo-Guijarro MJ, Ruiz-Hermosa A, Sánchez-López M. Prevalence of probable attention-deficit/hyperactivity disorder symptoms: result from a Spanish sample of children. BMC Pediatr. 2018;18(1):111.CrossRef Cerrillo-Urbina AJ, García-Hermoso A, Martínez-Vizcaíno V, Pardo-Guijarro MJ, Ruiz-Hermosa A, Sánchez-López M. Prevalence of probable attention-deficit/hyperactivity disorder symptoms: result from a Spanish sample of children. BMC Pediatr. 2018;18(1):111.CrossRef
9.
go back to reference Spencer TJ. ADHD and comorbidity in childhood. J Clin Psychiatry. 2006;67:27–31.CrossRef Spencer TJ. ADHD and comorbidity in childhood. J Clin Psychiatry. 2006;67:27–31.CrossRef
10.
go back to reference Courtabessis E, Pupier F, Surig L, Picot M-C, Nogué E, Macioce V, et al. Clinical factors associated with decision to recommend methylphenidate treatment for children with ADHD in France. Eur Child Adolescent Psychiatry. 2018;27(3):367–76.CrossRef Courtabessis E, Pupier F, Surig L, Picot M-C, Nogué E, Macioce V, et al. Clinical factors associated with decision to recommend methylphenidate treatment for children with ADHD in France. Eur Child Adolescent Psychiatry. 2018;27(3):367–76.CrossRef
11.
go back to reference Resnick RJ. Attention deficit hyperactivity disorder in teens and adults: they don't all outgrow it. J Clin Psychol. 2005;61(5):529–33.CrossRef Resnick RJ. Attention deficit hyperactivity disorder in teens and adults: they don't all outgrow it. J Clin Psychol. 2005;61(5):529–33.CrossRef
12.
go back to reference Polanczyk G, De Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatr. 2007;164(6):942–8.CrossRef Polanczyk G, De Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatr. 2007;164(6):942–8.CrossRef
13.
go back to reference Kim B-N, Kim Y-N, Cheong U-S, Kim J-W, Hwang J-W, Shin M-S, et al. Switching from methylphenidate-immediate release (MPH-IR) to methylphenidate-OROS (OROS-MPH): a multi-center, open-label study in Korea. Clin Psychopharmacol Neurosci. 2011;9(1):29.CrossRef Kim B-N, Kim Y-N, Cheong U-S, Kim J-W, Hwang J-W, Shin M-S, et al. Switching from methylphenidate-immediate release (MPH-IR) to methylphenidate-OROS (OROS-MPH): a multi-center, open-label study in Korea. Clin Psychopharmacol Neurosci. 2011;9(1):29.CrossRef
15.
go back to reference Vogenberg FR, Barash CI, Pursel M. Personalized medicine: part 1: evolution and development into theranostics. Pharm Ther. 2010;35(10):560. Vogenberg FR, Barash CI, Pursel M. Personalized medicine: part 1: evolution and development into theranostics. Pharm Ther. 2010;35(10):560.
16.
go back to reference Guidi GC, Lippi G. Will “personalized medicine” need personalized laboratory approach? Clin Chim Acta. 2009;400(1–2):25–9.CrossRef Guidi GC, Lippi G. Will “personalized medicine” need personalized laboratory approach? Clin Chim Acta. 2009;400(1–2):25–9.CrossRef
17.
go back to reference Alemi F, Erdman H, Griva I, Evans CH. Improved statistical methods are needed to advance personalized medicine. Open Transl Med J. 2009;1:16.CrossRef Alemi F, Erdman H, Griva I, Evans CH. Improved statistical methods are needed to advance personalized medicine. Open Transl Med J. 2009;1:16.CrossRef
20.
go back to reference Shahabian A, Shahim S, Bashash L, Yousefi F. Psychometry, factor analysis, and reliability of Conner rating scale for children 6-11 in shiraz: parents short form. Q J Psychol Stud. 2007;3(3):97–120 (In Persian). Shahabian A, Shahim S, Bashash L, Yousefi F. Psychometry, factor analysis, and reliability of Conner rating scale for children 6-11 in shiraz: parents short form. Q J Psychol Stud. 2007;3(3):97–120 (In Persian).
21.
go back to reference Conners C. Conners' rating scales-revised. North Tonawanda, New York: Multi-Health Systems. Inc; 1997. Conners C. Conners' rating scales-revised. North Tonawanda, New York: Multi-Health Systems. Inc; 1997.
22.
go back to reference Dalsgaard S, Østergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet. 2015;385(9983):2190–6.CrossRef Dalsgaard S, Østergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet. 2015;385(9983):2190–6.CrossRef
23.
go back to reference Diaz FJ. Measuring the individual benefit of a medical or behavioral treatment using generalized linear mixed-effects models. Stat Med. 2016;35(23):4077–92.CrossRef Diaz FJ. Measuring the individual benefit of a medical or behavioral treatment using generalized linear mixed-effects models. Stat Med. 2016;35(23):4077–92.CrossRef
24.
go back to reference Diaz FJ, Yeh H-W, de Leon J. Role of statistical random-effects linear models in personalized medicine. Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics). 2012;10(1):22–32.CrossRef Diaz FJ, Yeh H-W, de Leon J. Role of statistical random-effects linear models in personalized medicine. Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics). 2012;10(1):22–32.CrossRef
25.
go back to reference Diaz FJ, Cogollo MR, Spina E, Santoro V, Rendon DM, de Leon J. Drug dosage individualization based on a random-effects linear model. J Biopharm Stat. 2012;22(3):463–84.CrossRef Diaz FJ, Cogollo MR, Spina E, Santoro V, Rendon DM, de Leon J. Drug dosage individualization based on a random-effects linear model. J Biopharm Stat. 2012;22(3):463–84.CrossRef
26.
go back to reference Diaz FJ, Santoro V, Spina E, Cogollo M, Rivera T, Botts S, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry. 2008;41(03):81–91.CrossRef Diaz FJ, Santoro V, Spina E, Cogollo M, Rivera T, Botts S, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry. 2008;41(03):81–91.CrossRef
27.
go back to reference Diaz FJ, Rivera TE, Josiassen RC, Jd L. Individualizing drug dosage by using a random intercept linear model. Stat Med. 2007;26(9):2052–73.CrossRef Diaz FJ, Rivera TE, Josiassen RC, Jd L. Individualizing drug dosage by using a random intercept linear model. Stat Med. 2007;26(9):2052–73.CrossRef
28.
go back to reference Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2018;6:CD007990.PubMed Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2018;6:CD007990.PubMed
29.
go back to reference Castellanos FX, Giedd JN, Elia J, Marsh WL, Ritchie GF, Hamburger SD, et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry. 1997;36(5):589–96.CrossRef Castellanos FX, Giedd JN, Elia J, Marsh WL, Ritchie GF, Hamburger SD, et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry. 1997;36(5):589–96.CrossRef
30.
go back to reference Gadow KD, Nolan E, Sprafkin J, Sverd J. School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. J Dev Behav Pediatr. 1995;16(3):167–76.CrossRef Gadow KD, Nolan E, Sprafkin J, Sverd J. School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. J Dev Behav Pediatr. 1995;16(3):167–76.CrossRef
31.
go back to reference Tourette's Syndrome Study G. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58(4):527–36.CrossRef Tourette's Syndrome Study G. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58(4):527–36.CrossRef
Metadata
Title
Individualizing the dosage of Methylphenidate in children with attention deficit hyperactivity disorder
Authors
Hoda Shirafkan
Javad Mahmoudi-Gharaei
Akbar Fotouhi
Seyyed Ali Mozaffarpur
Mehdi Yaseri
Mostafa Hoseini
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2020
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/s12874-020-00934-y

Other articles of this Issue 1/2020

BMC Medical Research Methodology 1/2020 Go to the issue